Business Context and Reporting Period
This Form 8-K Current Report was filed by Reneo Pharmaceuticals, Inc. (trading symbol: RPHM) on August 2, 2022. The report discloses a corporate governance event: the appointment of a new Class I director to the Board of Directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel appointments and compensation arrangements rather than financial performance.
Material Changes
The material change disclosed is the appointment of Roshawn Blunt as a Class I director, effective August 2, 2022. Her term expires at the 2025 annual meeting of stockholders. The filing confirms no prior arrangements influenced her selection and no related party transactions requiring disclosure under Item 404(a) of Regulation S-K exist.
Compensation and Governance Details
- Cash Retainer: Ms. Blunt will receive an annual cash retainer of $40,000 for Board service.
- Initial Option Grant: An option to purchase 35,000 shares of common stock was granted on the appointment date, vesting in equal monthly installments over three years.
- Future Annual Grants: The policy provides for automatic annual option grants of 17,500 shares on the date of each annual meeting (pro-rated for the first year), vesting in full one year after the grant date or prior to the next annual meeting.
- Change in Control: All option grants vest in full upon a change in control as defined in the Company's 2021 Equity Incentive Plan.
- Indemnification: Ms. Blunt has entered into the Company's standard Indemnification Agreement.
Investor Verification Checklist
- Verify the total number of outstanding shares and the dilution impact of the 35,000 initial option grant and future annual grants.
- Review the Company's 2021 Equity Incentive Plan to confirm the specific definition of "change in control" triggering accelerated vesting.
- Confirm the pro-ration calculation for Ms. Blunt's first annual option grant based on the timing of the next annual stockholder meeting.
- Check subsequent filings for any changes to the Board composition or the Non-Employee Director Compensation Policy.